XORTX is a pharmaceutical company with two clinically advanced products in development: 1) XORTX's lead, XRx-008 program for ADPKD; and 2) XORTX's secondary program in XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, the company is dedicated to developing medications to improve the quality of life and future health of patients.